Dr. Hastings is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
747 52nd Street
Oakland, CA 94609Phone+1 510-428-3631Fax+1 510-601-3916
Education & Training
- Children's Hospital-OaklandFellowship, Pediatric Hematology/Oncology, 1989 - 1992
- Children's Hospital-OaklandResidency, Pediatrics, 1986 - 1989
- University of California, Davis, School of MedicineClass of 1986
Certifications & Licensure
- CA State Medical License 1987 - 2026
- NV State Medical License 1992 - 2019
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes Start of enrollment: 2004 Nov 01
- PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children Start of enrollment: 2012 Dec 13
- Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas Start of enrollment: 2014 Apr 29
- Join now to see all
Publications & Presentations
PubMed
- The Utility of Serum Alpha-fetoprotein for Monitoring for Relapse of Alpha-fetoprotein-Positive Hepatoblastoma.Monica Davini, Caroline Hastings, James Feusner
Journal of Pediatric Hematology/oncology. 2024-05-01 - The ASPHO 2023 Distinguished Career Award goes to Dr. A. Kim Ritchey.Caroline Hastings
Pediatric Blood & Cancer. 2023-06-01 - 5 citationsThe American Society of Pediatric Hematology Oncology workforce, productivity, and fellowship assessment: Current state of the workforce.Caroline Hastings, Scott C Borinstein, D John Bergsagel, J Nathan Hagstrom, Ryan Hooker
Pediatric Blood & Cancer. 2023-05-01
Press Mentions
- Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)October 18th, 2022
- Cyclo Therapeutics Provides Business UpdateSeptember 29th, 2022
- Cyclo Therapeutics Appoints Caroline Hastings, M.D. As Global Principal Investigator for Ongoing TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick DiseaseDecember 9th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: